RxDoctor Payments Data

Renato Sartori, MD

Neurology · San Juan, PRNPI 1902894587

Payments from drug & device makers

$652in general payments, 2019–2025

Across 17 payments — averaging $38.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amneal Pharmaceuticals LLC$191
  • Biohaven Pharmaceutical Holding Company Ltd.$100
  • Merck$100
  • E.r. Squibb & Sons, L.L.C.$99
  • Medtronic$46
  • Neurelis, Inc.$33
  • plus $83 from 3 others

What the payments were for

  • Food & beverage$652100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$652 in reported general payments places this provider in the 35th percentile of 129 neurology providers in Puerto Rico.

See all neurology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$22,906
Medicare patients
29
Services billed
115

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa44$20,177
Galantamine ErGalantamine Hbr190$15,380
Emgality PenGalcanezumab-Gnlm14$10,712
Carbidopa-Levodopa ErCarbidopa/Levodopa62$3,117
Memantine Hcl ErMemantine Hcl31$2,676
Galantamine Hbr58$2,301
Modafinil11$2,293
Donepezil Hcl44$2,282
Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide59$2,056
Ropinirole Hcl109$1,925
Ropinirole ErRopinirole Hcl20$1,720
Oxcarbazepine56$1,638
Selegiline Hcl17$1,131
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide73$1,002
Rivastigmine11$984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$191$20,17744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 129 neurology providers in Puerto Rico.

Other neurology in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →